Thibaudeau
Emmanuel Thibaudeau, Duclair FR
Patent application number | Description | Published |
---|---|---|
20120193414 | CARD PERSONALIZATION DEVICE FOR PRODUCING A PORTABLE USB OBJECT, ASSOCIATED CARD, METHOD FOR DETECTING THE TYPE OF CARD, AND USE OF THE CARDS IN A MASS MAILING METHOD - A card personalization device for producing a portable USB object having a device that is capable of recognizing cards that are operating according to the ISO standard and cards operating according to the USB standard. The recognition device being coupled to a device for switching the power supply terminals on the contact pads corresponding to the USB or ISO power supply contacts of the card in accordance with the type of the detected card. | 08-02-2012 |
Karen Thibaudeau, Montreal CA
Patent application number | Description | Published |
---|---|---|
20090312259 | LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS - This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus. | 12-17-2009 |
20110071082 | LONG LASTING ANTI-ANGIOGENIC PEPTIDES - Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect. | 03-24-2011 |
Karen Thibaudeau, Rosemere CA
Patent application number | Description | Published |
---|---|---|
20090054332 | THOMBOPOIETIN PEPTIDE CONJUGATES - The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides. The present invention also provides methods for the treatment and prevention of a disease or disorder comprising the administration of one or more of the compounds or conjugates of the invention to a subject in need of such treatment or prevention. | 02-26-2009 |
20090099074 | MODULATING FOOD INTAKE - The present disclosure relates to a conjugate comprising a PYY peptide or a functional derivative thereof which is coupled to a reactive group. Such a reactive group reacts with albumin so as to form a stable covalent bond therewith. The disclosure further provides methods of reducing water or food intake and reducing food intake between meals by administering such conjugates. | 04-16-2009 |
20090175821 | Modified therapeutic peptides with extended half-lives in vivo - A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity. | 07-09-2009 |
Laurent Thibaudeau, Poitiers FR
Patent application number | Description | Published |
---|---|---|
20110116097 | METHOD FOR POSITIONING THE MIRRORS OF A TRIPLE AXIS LASER GYROMETER, IN PARTICULAR WHEN STARTING THE GYROMETER - In a method for positioning three translatable mirrors in a device that includes three laser cavities arranged in a ring, each of the three laser cavities includes an optical amplification medium that can be excited to generate light waves. Each of the three laser cavities also includes an optical cavity formed by a set of mirrors including two of the translatable mirrors, the length of the optical cavity depending on the position of the two translatable mirrors, wherein the two translatable mirrors can be moved within position ranges imparting to the optical cavity lengths at which the amplification medium generates at least one laser wave. Each of the three translatable mirrors is used in the formation of two of the three optical cavities. The method includes the phase of prepositioning the three mirrors at an initial triplet of predetermined respective positions. The method also includes the phase of simultaneously moving in translation the three mirrors within ranges having a same amplitude that is lower than or equal to the intermode of the optical cavity having the highest intermode, to ensure that each of the optical cavities has a length for which the amplification medium provides a maximum gain. The intensities of the laser waves flowing respectively through each of the optical cavities are measured for each triplet of positions assumed by the mirrors. The method also includes the phase of determining, from the three triplets of mirror positions that respectively allowed each of the three cavities to provide a maximum intensity, the length of each of the three cavities at which the cavity provides a maximum intensity. The method further includes the phase of determining a single final triplet of mirror positions for simultaneously imparting to the three lengths at which they provide a maximum intensity. The method also includes the phase of positioning the mirrors according to the final position triplet. The invention can be used in positioning and navigation. | 05-19-2011 |